Ticker >

Samrat Pharmachem share price

Samrat Pharmachem Ltd.

BSE: 530125 SECTOR: Pharmaceuticals & Drugs  17k   134   14

333.45
-6.35 (-1.87%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 350

Today's Low

₹ 330.1

52 Week High

₹ 604.3

52 Week Low

₹ 320

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

103.03 Cr.

Enterprise Value

109.79 Cr.

No. of Shares

0.31 Cr.

P/E

4683.29

P/B

1.62

Face Value

₹ 10

Div. Yield

0.3 %

Book Value (TTM)

₹  205.85

CASH

11.89 Cr.

DEBT

18.66 Cr.

Promoter Holding

48.64 %

EPS (TTM)

₹  0.07

Sales Growth

40.09%

ROE

30.25 %

ROCE

34.91%

Profit Growth

-3.23 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year40.09%
3 Year31.23%
5 Year27.3%

Profit Growth

1 Year-3.23%
3 Year57.75%
5 Year38.9%

ROE%

1 Year30.25%
3 Year31.66%
5 Year24.41%

ROCE %

1 Year34.91%
3 Year37.05%
5 Year29.07%

Debt/Equity

0.2955

Price to Cash Flow

-10.92

Interest Cover Ratio

19.2921165868312

CFO/PAT (5 Yr. Avg.)

0.309020104315754

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 48.64 0
Sep 2023 48.64 0
Jun 2023 48.64 0
Mar 2023 48.64 0
Dec 2022 48.64 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 31.2310205221636% for the Past 3 years.
  • Company has been maintaining healthy ROE of 31.657719715787% over the past 3 years.
  • Company has been maintaining healthy ROCE of 37.0464640728495% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 19.2921165868312.
  • The company has an efficient Cash Conversion Cycle of 45.8022650341524 days.

 Limitations

  • Company has negative cash flow from operations of -9.4368.
  • The company is trading at a high EV/EBITDA of 70.4133.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 83.85 69.18 57.5 79.75 61.67
Total Expenditure 80.57 69.67 56.71 79.51 61.56
Operating Profit 3.28 -0.49 0.79 0.23 0.11
Other Income 0.28 0.03 0.34 0.3 0.42
Interest 0.62 0.17 0.22 0.13 0.23
Depreciation 0.16 0.16 0.16 0.16 0.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.77 -0.79 0.75 0.24 0.14
Tax 0.68 -0.05 0.14 0.43 -0.2
Profit After Tax 2.1 -0.75 0.61 -0.19 0.34
Adjusted EPS (Rs) 6.78 -2.41 1.98 -0.61 1.11

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 111.14 137.45 179.02 221.75 310.65
Total Expenditure 107.96 130.82 170.35 197.51 286.72
Operating Profit 3.18 6.63 8.67 24.24 23.93
Other Income 0.46 0.57 0.46 0.63 0.48
Interest 1.06 0.98 1.28 0.67 1.23
Depreciation 0.42 0.43 0.49 0.59 0.64
Exceptional Items 0 -0.01 -0.02 0 0
Profit Before Tax 2.16 5.78 7.34 23.6 22.53
Tax 0.62 1.55 2.01 6.42 5.9
Net Profit 1.54 4.24 5.33 17.18 16.63
Adjusted EPS (Rs.) 4.97 13.71 17.26 55.62 53.83

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 3.09 3.09 3.09 3.09 3.09
Total Reserves 16.98 21.21 26.55 43.73 60.05
Borrowings 0.63 0 0 0 0
Other N/C liabilities 0.52 0.14 0.43 0.46 0.25
Current liabilities 19.33 33.9 27.33 37.33 52.75
Total Liabilities 40.23 58.35 57.4 84.61 116.15
Assets
Net Block 6.86 7.19 9.4 9.99 10.7
Capital WIP 0 1.08 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 1.86
Loans & Advances 0.51 0.4 0.65 0.8 0.91
Other N/C Assets 0.1 0 0.02 2.56 4.06
Current Assets 32.76 49.68 47.32 71.26 98.62
Total Assets 40.23 58.35 57.4 84.61 116.15
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 2.16 5.79 7.34 23.6 22.53
Adjustment 1.4 1.39 1.7 1.19 1.65
Changes in Assets & Liabilities 0.47 -7.62 -1.99 -5.78 -24.12
Tax Paid -1.65 -0.87 -2.25 -1.53 -9.5
Operating Cash Flow 2.37 -1.33 4.8 17.47 -9.44
Investing Cash Flow 2.18 -1.92 -2.92 -1.06 -3.01
Financing Cash Flow -3.92 2 -1.89 -1.95 9.6
Net Cash Flow 0.63 -1.25 -0.02 14.46 -2.84

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 48.64 48.64 48.64 48.64 48.64
falguni kaushal mehta 2.15 2.15 2.15 2.15 2.15
jaya lalit mehta 3.86 3.86 3.86 3.86 3.86
kalpana premal mehta 1.64 1.64 1.64 1.64 1.64
kaushal lalit mehta 4.50 4.50 4.50 4.50 4.50
lalit damodar mehta 13.97 13.97 13.97 13.97 13.97
maitri megh mehta 0.27 0.27 0.27 0.27 0.27
megh rajesh mehta 1.51 1.51 1.51 1.51 1.51
premal lalit mehta 5.67 5.67 5.67 5.67 5.67
rajesh lalit mehta 12.41 12.41 12.41 12.41 12.41
rupal rajesh mehta 2.66 2.66 2.66 2.66 2.66
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 51.36 51.36 51.36 51.36 51.36
anshul specialty molecule... 1.63 1.63 1.63 1.31 1.31
lloyds securities oversea... 3.24 3.24 3.24 3.24 3.24
llp - - 0.07 0.03 0.03
sangeetha s 3.27 3.27 3.27 3.27 3.27
sharad kanayalal shah 1.13 1.13 1.13 1.13 1.13
alert consultants & credi... 1.38 1.43 1.53 - -
golechha global finance l... 2.84 2.56 2.11 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Samrat Pharmachem - Quaterly Results14 Feb 2024, 4:06PM Samrat Pharmachem - Quaterly Results14 Feb 2024, 4:06PM Samrat Pharmachem informs about newspapers advertisement23 Nov 2023, 5:20PM Samrat Pharmachem informs about press release18 Sep 2023, 5:08PM Samrat Pharmachem informs about record date for dividend payment 8 Sep 2023, 5:16PM Samrat Pharmachem - Quaterly Results14 Aug 2023, 3:57PM Samrat Pharmachem informs about loss of share certificates9 Aug 2023, 3:14PM Samrat Pharmachem informs about issuance of duplicate share certificates24 Jul 2023, 5:12PM Samrat Pharmachem informs about issuance of duplicate share certificate22 May 2023, 12:32PM Samrat Pharmachem informs about non-applicability of large corporate entity 10 May 2023, 3:07PM Samrat Pharmachem informs about certificate 12 Apr 2023, 4:05PM Samrat Pharmachem informs about issuance of duplicate share certificate3 Apr 2023, 4:46PM Samrat Pharmachem informs about trading window closure28 Mar 2023, 4:47PM Samrat Pharmachem informs about loss of share certificate24 Mar 2023, 4:38PM Samrat Pharmachem informs about issuance of duplicate certificate30 Jan 2023, 5:23PM Samrat Pharmachem - Quaterly Results14 Nov 2022, 3:32PM Samrat Pharmachem informs about compliance certificate12 Oct 2022, 5:11PM Samrat Pharmachem informs about outcome of AGM3 Oct 2022, 4:54PM Samrat Pharmachem informs about approval of un-audited financial results 10 Feb 2022, 5:00PM Samrat Pharmachem - Quaterly Results10 Feb 2022, 3:41PM Samrat Pharmachem - Quaterly Results10 Feb 2022, 3:41PM Samrat Pharmachem - Quaterly Results10 Feb 2022, 3:41PM Samrat Pharmachem informs about newspaper publication19 Nov 2021, 1:37PM Samrat Pharmachem informs about newspaper advertisement17 Feb 2021, 4:20PM Samrat Pharmachem informs about newspaper publication24 Dec 2020, 3:15PM

Samrat Pharmachem Stock Price Analysis and Quick Research Report. Is Samrat Pharmachem an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Samrat Pharmachem and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Samrat Pharmachem cash from the operating activity was Rs -9.4368 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Samrat Pharmachem has a Debt to Equity ratio of 0.2955 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Samrat Pharmachem , the EPS growth was -3.22548166473689 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Samrat Pharmachem has OPM of 7.70246766495228 % which is a bad sign for profitability.
     
  • ROE: Samrat Pharmachem have a healthy ROE of 30.2468967398718 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Samrat Pharmachem is Rs 333.45. One can use valuation calculators of ticker to know if Samrat Pharmachem share price is undervalued or overvalued.
Last Updated on:
Brief about Samrat Pharmachem
X